Cas no 179324-69-7 (Bortezomib)

Bortezomib is a proteasome inhibitor that disrupts cancer cell growth by blocking protein degradation. Its key advantages lie in its ability to induce apoptosis and stabilize cytotoxic proteins, ultimately leading to the death of malignant plasma cells in multiple myeloma patients, while minimizing toxicity to normal cells.
Bortezomib structure
Bortezomib structure
Product Name:Bortezomib
CAS No:179324-69-7
MF:C19H25BN4O4
MW:384.2372
MDL:MFCD27978443
CID:66122
PubChem ID:387447
Update Time:2025-08-28

Bortezomib Chemical and Physical Properties

Names and Identifiers

    • Bortezomib
    • MG-341
    • PS-341
    • [(1r)-3-methyl-1-[[(2s)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]-boronic acid
    • dpba
    • VELCADE
    • VELCADE(BORTEZOMIB)
    • Boronic acid, B-[(1R)-3-methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(2-pyrazinylcarbonyl)amino]propyl]amino]butyl]-
    • Bortezomib for research
    • Bortezomib (PS-341)
    • ((R)-3-Methyl-1-((S)-3-phenyl-2-(pyrazine-2-carboxamido)propanamido)butyl)boronic acid
    • bortezomib（Velcade?, Bortecad?, PS-341,MG-341）
    • Bortizomib
    • &nbsp
    • Bortezmib
    • Bortezomib Base
    • MG-341 PS-341
    • PS341
    • Radiciol
    • MLM341
    • BortezoMib R
    • BortezoMib-D8
    • MG-341 PS-341
    • Ps 341
    • N-[(1R)-1-(DIHYDROXYBORYL)-3-METHYLBUTYL]-N-(PYRAZIN-2-YLCARBONYL)-L-PHENYLALANINAMIDE
    • Bortezomib (Velcade)
    • [(1R)-3-methyl-1-[[(2S)-3-phenyl-2-(pyrazine-2-carbonylamino)propanoyl]amino]butyl]boronic acid
    • [(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic acid
    • Peptide boronate
    • 69G8BD63PP
    • Boronic acid, B-[(1R)-3-methyl-1-[[(2S)-1-oxo-3-phenyl
    • LDP-341
    • PS 341 (pharmaceutical)
    • Radiciol , NSC 681239 , MG 341 , DPBA , Brotezamide , LDP 341
    • CHEBI:52717
    • S1013
    • (1R)-3-Methyl-1-({(2S)-3-phenyl-2-[(2-pyrazinylcarbonyl)amino]propanoyl}amino)butylboronic acid, AldrichCPR
    • HB4036
    • NCGC00242506-07
    • Bortezomib accord
    • NSC-756655
    • EN300-657180
    • Bortezomib [USAN:INN:BAN]
    • MLS004774142
    • L01XX32
    • HY-10227
    • D03150
    • BORTEZOMIB (MART.)
    • NSC-681239
    • Velcade (Millenium)
    • AB01273951-01
    • NSC756655
    • BORTEZOMIB [JAN]
    • SR-01000939863-2
    • Boronic acid, [(1(R)-3-methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]-
    • SW208077-3
    • [(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]-butyl]boronic acid
    • N-((1R)-1-(DIHYDROXYBORYL)-3-methylbutyl)-N-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide
    • (R)-3-methyl-1-((S)-3-phenyl-2-(pyrazine-2-carboxamido)propanamido)butylboronic acid
    • NCI60_029010
    • Bortezomib (Velcade,MG-341,PS-341)?
    • ((R)-3-methyl-1-((S)-3-phenyl-2-(pyrazine-2-carboxamido)propanamido)butyl)boronicacid
    • CS-1039
    • BORTEZOMIB [INN]
    • [(1R)-3-methyl-1-({(2S)-3-phenyl-2-[(pyrazin-2-ylcarbonyl)amino]propanoyl}amino)butyl]boronic acid
    • NSC681239
    • NSC 681239
    • 3mg0
    • BORTEZOMIB [VANDF]
    • [(1R)-3-methyl-1-[(2S)-3-phenyl-2-[(pyrazin-2-yl)formamido]propanamido]butyl]boronic acid
    • CAS-179324-69-7
    • DTXCID1020980
    • 179324-69-7
    • BORTEZOMIB [ORANGE BOOK]
    • CHEMBL325041
    • Bortexomib
    • MLN-341
    • BORTEZOMIB [MI]
    • DTXSID3040980
    • BORTEZOMIB [MART.]
    • EX-A8373
    • N-((1S)-1-benzyl-2-(((1R)-1-(dihydroxyboranyl)-3-methylbutyl)amino)2-oxoethylpyrazinecarboxamide
    • Bortezomib for Injection
    • BORTEZOMIB HYDRATE [JAN]
    • NCGC00242506-02
    • bortezomibum
    • Bortezomib [USAN]
    • SMR003500787
    • MG 341
    • AB01273951-02
    • Bortezomib- Bio-X
    • Bortezomib hydrate
    • N-((1R)-1-(dihydroxyboranyl)-3-methylbutyl)-N(alpha)-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide
    • UNII-69G8BD63PP
    • N-((1S)-1-Benzyl-2-(((1R)-1-(dihydroxyboranyl)-3-methylbutyl)amino)-2-oxoethyl)pyrazinecarboxamide
    • Q419319
    • LDP 341
    • (R)-3-METHYL-1-((S)-3-PHENYL-2-(PYRAZINE-2-CARBOXAMIDO)PROPANAMIDO)BUTAN-2-YLBORONIC ACID
    • Tox21_112630
    • C19H25BN4O4
    • Tox21_112672_1
    • BRD-K88510285-001-17-8
    • B5741
    • ((1R)-3-Methyl-1-(((2S)-3-phenyl-2-((pyrazinylcarbonyl)amino)propanoyl)amino)butyl)boronic acid
    • Bortezomib,Velcade
    • BORTEZOMIB [EMA EPAR]
    • [(1R)-3-Methyl-1-[[(2S)-3-phenyl-2-[(pyrazinylcarbonyl)amino]propanoyl]amino]butyl]boronic acid
    • AS-15721
    • BORTEZOMIB [WHO-DD]
    • Z2213886907
    • PROSCRIPT BORONIC ACID
    • GTPL6391
    • NCGC00181022-01
    • Boronic acid, (3-methyl-1-((1-oxo-3-phenyl-2-((pyrazinylcarbonyl)amino)propyl)amino)butyl)-, (S-(R*,S*))-
    • BRD-K88510285-001-02-0
    • AB01273951_03
    • NS00006197
    • Pyz-Phe-boroLeu
    • BORTEZOMIB [HSDB]
    • BRD-K88510285-001-11-1
    • HSDB 7666
    • LPD 341
    • Tox21_112672
    • PS-341 [Bortezomib]
    • NCGC00242506-06
    • NCGC00242506-01
    • (R)-3-methyl-1-((S)-3-phenyl-2-(pyrazine-6-carboxamido)propanamido)butylboronic acid
    • 1610526-91-4
    • Boronic acid, ((1R)-3-methyl-1-(((2S)-1-oxo-3-phenyl-2-((pyrazinylcarbonyl)amino)propyl)amino)butyl)-
    • BDBM50069989
    • DB00188
    • Bortezomib (JAN/USAN/INN)
    • CCG-268449
    • SR-01000939863
    • MFCD09056737
    • N-[(1R)-1-(dihydroxyboranyl)-3-methylbutyl]-Nalpha-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide
    • SCHEMBL192129
    • N-[(1R)-1-(dihydroxyboranyl)-3-methylbutyl]-N(alpha)-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide
    • AKOS015909706
    • Velcade (TN)
    • BB164258
    • NCGC00168751-01
    • BRD-K88510285-001-18-6
    • LPD-341
    • MDL： MFCD27978443
    • Inchi： 1S/C19H25BN4O4/c1-13(2)10-17(20(27)28)24-18(25)15(11-14-6-4-3-5-7-14)23-19(26)16-12-21-8-9-22-16/h3-9,12-13,15,17,27-28H,10-11H2,1-2H3,(H,23,26)(H,24,25)/t15-,17-/m0/s1
    • InChI Key： GXJABQQUPOEUTA-RDJZCZTQSA-N
    • SMILES： CC(C[C@H](NC([C@@H](NC(C1=CN=CC=N1)=O)CC1=CC=CC=C1)=O)B(O)O)C

Computed Properties

  • Exact Mass: 384.19700
  • Monoisotopic Mass: 384.197
  • Isotope Atom Count: 0
  • Hydrogen Bond Donor Count: 4
  • Hydrogen Bond Acceptor Count: 6
  • Heavy Atom Count: 28
  • Rotatable Bond Count: 9
  • Complexity: 500
  • Covalently-Bonded Unit Count: 1
  • Defined Atom Stereocenter Count: 2
  • Undefined Atom Stereocenter Count : 0
  • Defined Bond Stereocenter Count: 0
  • Undefined Bond Stereocenter Count: 0
  • Topological Polar Surface Area: 124

Experimental Properties

  • Color/Form: Powder
  • Density: 1.214
  • Melting Point: 139-143°C
  • Boiling Point: 684.30° C
  • Flash Point: No data available
  • Refractive Index: 1.56
  • Solubility: Soluble in chloroform, dimethyl sulfoxide, ethanol and methanol.
  • Stability/Shelf Life: Hygroscopic and Moisture Sensitive
  • PSA: 124.44000
  • LogP: 1.56230

Bortezomib Security Information

Bortezomib Customs Data

  • HS CODE：2934999090
  • Customs Data：

    China Customs Code:

    2934999090

    Overview:

    2934999090. Other heterocyclic compounds. VAT:17.0%. Tax refund rate:13.0%. Regulatory conditions:nothing. MFN tariff:6.5%. general tariff:20.0%

    Declaration elements:

    Product Name, component content, use to

    Summary:

    2934999090. other heterocyclic compounds. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%

Bortezomib Pricemore >>

Related Categories No. Product Name Cas No. Purity Specification Price update time Inquiry
SHANG HAI XIAN DING Biotechnology Co., Ltd.
A-DB936-100mg
Bortezomib
 179324-69-7 98%（NMR）
100mg
 294.0CNY 2021-08-03
SHANG HAI XIAN DING Biotechnology Co., Ltd.
A-DB936-250mg
Bortezomib
 179324-69-7 98%（NMR）
250mg
 681.0CNY 2021-08-03
Matrix Scientific
094031-1g
((R)-3-Methyl-1-((S)-3-phenyl-2-(pyrazine-2-carboxamido)propanamido)butyl)boronic acid, 98%
 179324-69-7 98%
1g
 $360.00 2023-09-10
TI XI AI ( SHANG HAI ) HUA CHENG GONG YE FA ZHAN Co., Ltd.
B5741-50MG
Bortezomib
 179324-69-7 >98.0%(HPLC)
50mg
 ￥490.00 2024-04-15
WU HAN AN JIE KAI Biomedical Technology Co., Ltd.
ajci19530-10mg
Bortezomib (PS-341)
 179324-69-7 98%
10mg
 ￥516.00 2023-09-09
WU HAN AN JIE KAI Biomedical Technology Co., Ltd.
ajci19530-25mg
Bortezomib (PS-341)
 179324-69-7 98%
25mg
 ￥893.00 2023-09-09
WU HAN AN JIE KAI Biomedical Technology Co., Ltd.
ajci19530-100mg
Bortezomib (PS-341)
 179324-69-7 98%
100mg
 ￥1964.00 2023-09-09
WU HAN AN JIE KAI Biomedical Technology Co., Ltd.
ajci19530-500mg
Bortezomib (PS-341)
 179324-69-7 98%
500mg
 ￥5352.00 2023-09-09
ChemScence
CS-1039-100mg
Bortezomib
 179324-69-7 99.97%
100mg
 $180.0 2022-04-27
ChemScence
CS-1039-250mg
Bortezomib
 179324-69-7 99.97%
250mg
 $71.0 2021-09-02

Bortezomib Suppliers

Suzhou Senfeida Chemical Co., Ltd
Gold Member
Audited Supplier Audited Supplier
(CAS:179324-69-7)Bortezomib
Order Number:sfd19491
Stock Status:in Stock
Quantity:200kg
Purity:99.9%
Pricing Information Last Updated:Friday, 19 July 2024 14:38
Price ($):discuss personally

Bortezomib Spectrogram

MS-MS
MS-MS
1H NMR 300 MHz DMSO
1H NMR
13C NMR
13C NMR

Bortezomib Related Literature

Related Categories

Additional information on Bortezomib

The Role and Recent Advancements of Bortezomib (CAS No: 179324-69-7) in Modern Medicine

Bortezomib, chemically designated as N-phenylmaleoyl-L-leucine amide, is a groundbreaking compound with the CAS number 179324-69-7. This proteasome inhibitor has revolutionized the treatment of multiple myeloma and has become a cornerstone in the management of certain hematologic malignancies. Its mechanism of action, targeting the ubiquitin-proteasome system, has opened new avenues in cancer therapy and continues to be a subject of extensive research.

The development of Bortezomib marked a significant milestone in the field of oncology. By specifically inhibiting the 26S proteasome, it disrupts the degradation of proteins that are essential for cancer cell survival, leading to apoptosis and growth inhibition. This targeted approach has demonstrated remarkable efficacy in clinical trials, particularly in patients with relapsed or refractory multiple myeloma. The compound's approval by regulatory agencies such as the FDA and EMA underscores its therapeutic potential and safety profile.

Recent studies have expanded the therapeutic applications of Bortezomib beyond multiple myeloma. Research indicates that it may also be effective in treating other hematologic malignancies, including mantle cell lymphoma and acute promyelocytic leukemia. The compound's ability to modulate the tumor microenvironment and enhance immune responses has been a focus of interest. Preclinical studies have shown promising results when Bortezomib is combined with immunotherapy agents, suggesting a synergistic effect that could improve patient outcomes.

The pharmacokinetic profile of Bortezomib is another area of active investigation. Its oral bioavailability and rapid clearance necessitate specific dosing regimens to maintain therapeutic levels. Advances in formulation technology have led to the development of more stable and bioavailable derivatives, improving patient compliance and efficacy. These innovations highlight the ongoing efforts to optimize the delivery and efficacy of this critical therapeutic agent.

One of the most significant challenges in Bortezomib therapy is the development of resistance. Cancer cells can adapt to evade its effects, leading to treatment failure. Understanding these mechanisms is crucial for developing strategies to overcome resistance. Recent research has identified several pathways that contribute to resistance, including mutations in proteasome subunits and upregulation of survival signaling pathways. Targeting these pathways in combination with Bortezomib could mitigate resistance and improve long-term treatment outcomes.

The role of Bortezomib in personalized medicine is also gaining traction. Genomic profiling can help identify patients who are more likely to benefit from this therapy or those at higher risk of developing adverse effects. By tailoring treatment regimens based on individual patient profiles, clinicians can maximize therapeutic benefits while minimizing risks. This approach aligns with the broader goals of precision medicine, where treatments are customized to individual patients' unique biological characteristics.

Future research directions for Bortezomib include exploring its potential in solid tumors and other non-hematologic malignancies. Preliminary studies suggest that its mechanism of action may be applicable to a wider range of cancers. Additionally, investigating its interactions with other therapeutic agents could lead to novel combination therapies that enhance efficacy and reduce toxicity.

The impact of Bortezomib extends beyond its direct therapeutic effects. It has paved the way for further research into proteasome inhibition as a therapeutic strategy. This has spurred the development of next-generation proteasome inhibitors with improved pharmacokinetic properties and reduced side effects. These advancements hold promise for addressing unmet medical needs in various cancer types.

In conclusion, Bortezomib (CAS No: 179324-69-7) represents a significant advancement in cancer therapy. Its ability to target cancer cells through inhibition of the ubiquitin-proteasome system has transformed treatment outcomes for patients with multiple myeloma and other hematologic malignancies. Ongoing research continues to uncover new applications and improve its therapeutic potential, making it a cornerstone in modern oncology.

179324-69-7 (Bortezomib) Related Products

Recommended suppliers
Suzhou Senfeida Chemical Co., Ltd
(CAS:179324-69-7)Bortezomib
sfd19491
Purity:99.9%
Quantity:200kg
Price ($):Inquiry
Email